FABP5 and neoplasm: Flow cytometry analysis revealed significant increases in CD80+CD86+ DCs (Figure 7B), CD8+CD3+ T cells (Figure 7C), and CD44+CD62L‐TEM cells (Figure 7D), indicating that FABP5 inhibition effectively enhanced immune responses in the tumor microenvironment.